Half-year report · Q2

Period2024-04-01 → 2024-09-30
Filed2024-11-07
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 45
MetricValuePeriodScopeSource row
Revenue¥1.24T2024-04-01 → 2024-09-30Cons.Revenue IFRS
Revenue¥2.45T2023-04-01 → 2024-03-31Cons.Revenue IFRS (5-year summary)
Revenue¥1.19T2023-04-01 → 2023-09-30Cons.Revenue IFRS
Operating income¥121.2bn2024-04-01 → 2024-09-30Cons.Operating profit loss IFRS
Operating income−¥133.7bn2023-04-01 → 2023-09-30Cons.Operating profit loss IFRS
Profit before tax−¥30.5bn2024-04-01 → 2024-09-30Cons.Profit loss before tax IFRS
Profit before tax−¥462.8bn2023-04-01 → 2024-03-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax−¥103.8bn2023-04-01 → 2023-09-30Cons.Profit loss before tax IFRS
Net income (owners)−¥6.5bn2024-04-01 → 2024-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)−¥311.8bn2023-04-01 → 2024-03-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)−¥76.3bn2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income−¥20.3bn2024-04-01 → 2024-09-30Cons.Profit loss IFRS
Net income−¥465.4bn2023-04-01 → 2024-03-31Cons.Profit loss IFRS (5-year summary)
Net income−¥107.0bn2023-04-01 → 2023-09-30Cons.Profit loss IFRS
Total assets¥3.72Tat 2024-09-30Cons.Assets IFRS
Total assets¥3.93Tat 2024-03-31Cons.Assets IFRS
Total assets¥4.38Tat 2023-09-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥2.63Tat 2024-09-30Cons.Liabilities IFRS
Total liabilities¥2.77Tat 2024-03-31Cons.Liabilities IFRS
Net assets / equity¥1.09Tat 2024-09-30Cons.Equity IFRS
Net assets / equity¥1.16Tat 2024-03-31Cons.Equity IFRS
Net assets / equity¥1.55Tat 2023-09-30Cons.Equity IFRS
Net assets / equity¥1.49Tat 2023-03-31dCons.Equity IFRS
Equity (owners)¥909.8bnat 2024-09-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥965.8bnat 2024-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥1.22Tat 2023-09-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥273.4bnat 2024-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥217.4bnat 2024-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥277.7bnat 2023-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥305.8bnat 2023-03-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥63.5bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow−¥51.3bn2023-04-01 → 2024-03-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow−¥115.3bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow¥74.4bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥112.2bn2023-04-01 → 2024-03-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥79.8bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥75.4bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow¥49.2bn2023-04-01 → 2024-03-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow¥140.2bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥-3.992024-04-01 → 2024-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥-190.692023-04-01 → 2024-03-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥-46.692023-04-01 → 2023-09-30Cons.Basic earnings loss per share IFRS
Equity ratio24.5%at 2024-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio24.5%at 2024-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio27.9%at 2023-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 62
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2024-04-01 → 2024-09-30¥78.9bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2024-04-01 → 2024-09-30¥41.6bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2024-04-01 → 2024-09-30¥37.3bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2024-04-01 → 2024-09-30¥15.7bn
Reconciling Itemsreconcilingrevenue2024-04-01 → 2024-09-30−¥50.2bn
Reconciling Itemsreconcilingrevenue intersegment2024-04-01 → 2024-09-30−¥50.2bn
Reconciling Itemsreconcilingsegment profit2024-04-01 → 2024-09-30−¥10.0bn
jpcrp040300-q2r_E00752-000Energy And Functional Materialsreportable segmentrevenue2024-04-01 → 2024-09-30¥147.5bn
jpcrp040300-q2r_E00752-000Energy And Functional Materialsreportable segmentrevenue external2024-04-01 → 2024-09-30¥138.8bn
jpcrp040300-q2r_E00752-000Energy And Functional Materialsreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥8.7bn
jpcrp040300-q2r_E00752-000Energy And Functional Materialsreportable segmentsegment profit2024-04-01 → 2024-09-30¥8.7bn
jpcrp040300-q2r_E00752-000Essential Chemicals And Plasticsreportable segmentrevenue2024-04-01 → 2024-09-30¥405.9bn
jpcrp040300-q2r_E00752-000Essential Chemicals And Plasticsreportable segmentrevenue external2024-04-01 → 2024-09-30¥403.0bn
jpcrp040300-q2r_E00752-000Essential Chemicals And Plasticsreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥2.9bn
jpcrp040300-q2r_E00752-000Essential Chemicals And Plasticsreportable segmentsegment profit2024-04-01 → 2024-09-30−¥36.6bn
jpcrp040300-q2r_E00752-000Health And Agriculture Relatedreportable segmentrevenue2024-04-01 → 2024-09-30¥239.5bn
jpcrp040300-q2r_E00752-000Health And Agriculture Relatedreportable segmentrevenue external2024-04-01 → 2024-09-30¥238.4bn
jpcrp040300-q2r_E00752-000Health And Agriculture Relatedreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥1.1bn
jpcrp040300-q2r_E00752-000Health And Agriculture Relatedreportable segmentsegment profit2024-04-01 → 2024-09-30¥13.6bn
jpcrp040300-q2r_E00752-000Information Electronic Chemistryreportable segmentrevenue2024-04-01 → 2024-09-30¥224.6bn
jpcrp040300-q2r_E00752-000Information Electronic Chemistryreportable segmentrevenue external2024-04-01 → 2024-09-30¥224.3bn
jpcrp040300-q2r_E00752-000Information Electronic Chemistryreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥235m
jpcrp040300-q2r_E00752-000Information Electronic Chemistryreportable segmentsegment profit2024-04-01 → 2024-09-30¥37.5bn
jpcrp040300-q2r_E00752-000Medical Productsreportable segmentrevenue2024-04-01 → 2024-09-30¥195.2bn
jpcrp040300-q2r_E00752-000Medical Productsreportable segmentrevenue external2024-04-01 → 2024-09-30¥195.2bn
jpcrp040300-q2r_E00752-000Medical Productsreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥1m
jpcrp040300-q2r_E00752-000Medical Productsreportable segmentsegment profit2024-04-01 → 2024-09-30¥470m
—segment totalrevenue2024-04-01 → 2024-09-30¥1.21T
—segment totalrevenue external2024-04-01 → 2024-09-30¥1.20T
—segment totalrevenue intersegment2024-04-01 → 2024-09-30¥13.0bn
—segment totalsegment profit2024-04-01 → 2024-09-30¥23.7bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2023-04-01 → 2023-09-30¥76.2bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2023-04-01 → 2023-09-30¥34.9bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2023-04-01 → 2023-09-30¥41.3bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2023-04-01 → 2023-09-30¥4.3bn
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-09-30−¥56.0bn
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-09-30−¥56.0bn
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-09-30−¥7.9bn
jpcrp040300-q2r_E00752-000Energy And Functional Materialsreportable segmentrevenue2023-04-01 → 2023-09-30¥159.8bn
jpcrp040300-q2r_E00752-000Energy And Functional Materialsreportable segmentrevenue external2023-04-01 → 2023-09-30¥149.9bn
jpcrp040300-q2r_E00752-000Energy And Functional Materialsreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥9.9bn
jpcrp040300-q2r_E00752-000Energy And Functional Materialsreportable segmentsegment profit2023-04-01 → 2023-09-30¥6.5bn
jpcrp040300-q2r_E00752-000Essential Chemicals And Plasticsreportable segmentrevenue2023-04-01 → 2023-09-30¥393.1bn
jpcrp040300-q2r_E00752-000Essential Chemicals And Plasticsreportable segmentrevenue external2023-04-01 → 2023-09-30¥390.3bn
jpcrp040300-q2r_E00752-000Essential Chemicals And Plasticsreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥2.8bn
jpcrp040300-q2r_E00752-000Essential Chemicals And Plasticsreportable segmentsegment profit2023-04-01 → 2023-09-30−¥44.4bn
jpcrp040300-q2r_E00752-000Health And Agriculture Relatedreportable segmentrevenue2023-04-01 → 2023-09-30¥243.1bn
jpcrp040300-q2r_E00752-000Health And Agriculture Relatedreportable segmentrevenue external2023-04-01 → 2023-09-30¥241.2bn
jpcrp040300-q2r_E00752-000Health And Agriculture Relatedreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥1.8bn
jpcrp040300-q2r_E00752-000Health And Agriculture Relatedreportable segmentsegment profit2023-04-01 → 2023-09-30−¥7.6bn
jpcrp040300-q2r_E00752-000Information Electronic Chemistryreportable segmentrevenue2023-04-01 → 2023-09-30¥203.9bn
jpcrp040300-q2r_E00752-000Information Electronic Chemistryreportable segmentrevenue external2023-04-01 → 2023-09-30¥203.7bn
jpcrp040300-q2r_E00752-000Information Electronic Chemistryreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥220m
jpcrp040300-q2r_E00752-000Information Electronic Chemistryreportable segmentsegment profit2023-04-01 → 2023-09-30¥17.8bn
jpcrp040300-q2r_E00752-000Medical Productsreportable segmentrevenue2023-04-01 → 2023-09-30¥166.9bn
jpcrp040300-q2r_E00752-000Medical Productsreportable segmentrevenue external2023-04-01 → 2023-09-30¥166.9bn
jpcrp040300-q2r_E00752-000Medical Productsreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥1m
jpcrp040300-q2r_E00752-000Medical Productsreportable segmentsegment profit2023-04-01 → 2023-09-30−¥65.5bn
—segment totalrevenue2023-04-01 → 2023-09-30¥1.17T
—segment totalrevenue external2023-04-01 → 2023-09-30¥1.15T
—segment totalrevenue intersegment2023-04-01 → 2023-09-30¥14.7bn
—segment totalsegment profit2023-04-01 → 2023-09-30−¥93.1bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 919
ItemContextValueUnit
Trade and other payables cl IFRSPrior1YearInstant543384000000JPY
Trade and other payables cl IFRSCurrentQuarterInstant527610000000JPY
Other financial liabilities cl IFRSPrior1YearInstant77610000000JPY
Other financial liabilities cl IFRSCurrentQuarterInstant68094000000JPY
Income taxes payable cl IFRSPrior1YearInstant8545000000JPY
Income taxes payable cl IFRSCurrentQuarterInstant27707000000JPY
Provisions cl IFRSPrior1YearInstant90919000000JPY
Provisions cl IFRSCurrentQuarterInstant88224000000JPY
Other current liabilities cl IFRSPrior1YearInstant129087000000JPY
Other current liabilities cl IFRSCurrentQuarterInstant112188000000JPY
Liabilities other than liabilities directly associated with assets held for sale IFRSPrior1YearInstant1435450000000JPY
Liabilities other than liabilities directly associated with assets held for sale IFRSCurrentQuarterInstant1269713000000JPY
Liabilities directly associated with assets held for sale IFRSPrior1YearInstant8037000000JPY
Liabilities directly associated with assets held for sale IFRSCurrentQuarterInstant16557000000JPY
Total current liabilities IFRSPrior1YearInstant1443487000000JPY
Total current liabilities IFRSCurrentQuarterInstant1286270000000JPY
Bonds and borrowings ncl IFRSPrior1YearInstant977581000000JPY
Bonds and borrowings ncl IFRSCurrentQuarterInstant1048496000000JPY
Other financial liabilities ncl IFRSPrior1YearInstant100144000000JPY
Other financial liabilities ncl IFRSCurrentQuarterInstant94247000000JPY
Retirement benefit liability ncl IFRSPrior1YearInstant30589000000JPY
Retirement benefit liability ncl IFRSCurrentQuarterInstant31049000000JPY
Provisions ncl IFRSPrior1YearInstant46059000000JPY
Provisions ncl IFRSCurrentQuarterInstant32310000000JPY
Deferred tax liabilities IFRSPrior1YearInstant121146000000JPY
Deferred tax liabilities IFRSCurrentQuarterInstant103163000000JPY
Other non current liabilities ncl IFRSPrior1YearInstant51446000000JPY
Other non current liabilities ncl IFRSCurrentQuarterInstant37005000000JPY
Non current labilities IFRSPrior1YearInstant1326965000000JPY
Non current labilities IFRSCurrentQuarterInstant1346270000000JPY
Liabilities IFRSPrior1YearInstant2770452000000JPY
Liabilities IFRSCurrentQuarterInstant2632540000000JPY
Share capital IFRSPrior1YearInstant89938000000JPY
Share capital IFRSCurrentQuarterInstant90059000000JPY
Capital surplus IFRSPrior1YearInstant237000000JPY
Capital surplus IFRSCurrentQuarterInstant322000000JPY
Retained earnings IFRSPrior1YearInstant578175000000JPY
Retained earnings IFRSCurrentQuarterInstant601343000000JPY
Treasury shares IFRSPrior1YearInstant-8355000000JPY
Treasury shares IFRSCurrentQuarterInstant-8358000000JPY
Other components of equity IFRSPrior1YearInstant304033000000JPY
Other components of equity IFRSCurrentQuarterInstant226235000000JPY
Other comprehensive income related to assets held for sale IFRSPrior1YearInstant1725000000JPY
Other comprehensive income related to assets held for sale IFRSCurrentQuarterInstant150000000JPY
Equity attributable to owners of parent IFRSPrior1YearInstant965753000000JPY
Equity attributable to owners of parent IFRSCurrentQuarterInstant909751000000JPY
Non controlling interests IFRSPrior1YearInstant198613000000JPY
Non controlling interests IFRSCurrentQuarterInstant176744000000JPY
Equity IFRSPrior1YearInstant1164366000000JPY
Equity IFRSCurrentQuarterInstant1086495000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2024-03-31pass
balance sheet identityconsolidated 2024-09-30pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2024-04-01/2024-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2024-04-01/2024-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2024-04-01/2024-09-30pass
statement vs summary · total assetsconsolidated 2024-03-31pass
statement vs summary · total assetsconsolidated 2024-09-30pass